Clinical trial NCT04123041: Characterize the Nicotine Uptake and Subjective Effects With Use of JUUL Electronic Nicotine Delivery Systems
Official title: A Randomized, Open-Label, Cross-Over Study to Characterize the Nicotine Uptake and Subjective Effects With Use of JUUL Electronic Nicotine Delivery Systems With Multiple Flavors and Nicotine Concentrations, Usual Brand of Combustible Cigarettes, a Comparator E-Cigarette and Nicotine Gum in Adult Smokers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Electronic Cigarette Use
Tobacco Smoking
Keywords: Electronic Nicotine Delivery System
Combustible Cigarettes
Nicotine
Lead sponsor: Juul Labs, Inc.
Sponsor class: INDUSTRY
First posted: 2019-10-10
Enrollment: 137
Sex: ALL
Minimum age (years): 21
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: The purpose of this study is to estimate nicotine uptake and assess subjective effects during ad libitum use sessions of 4 flavors of JUUL ENDS (also referred to as nicotine salt pod system; NSPS) products (i.e., Virginia Tobacco, Mint, Menthol and Mango) with 2 different nicotine concentrations. Subjective effects will also be assessed to gain an understanding of the user's experience during and after JUUL ENDS product use to evaluate the abuse liability of the products. The subject population will consist of healthy adult, male and female smokers, 21 to 65 years of age.


Eligibility criteria: Inclusion Criteria:

1. Provides voluntary consent to participate in this study documented on the signed informed consent form (ICF).
2. Adult, male or female smoker, 21 to 65 years of age, inclusive, at screening.
3. Has been a smoker for at least 12 months prior to screening. Brief periods of non-smoking (e.g., up to \~7 consecutive days due to illness, quit attempt (prior to 30 days of screening), participation in a study where smoking was prohibited) during the 12 months prior to screening will be permitted at the discretion of the Investigator.
4. Currently smokes an average of 10 or more king size or 100s manufactured combustible cigarettes per day (CPD; non-menthol or menthol), as reported at screening.
5. Has a positive urine cotinine (≥200 ng/mL) at screening.
6. Has an exhaled CO (carbon monoxide) \>10 ppm at screening.
7. A female subject of childbearing potential must have been using 1 of the following forms of contraception, and agree to continue using it through completion of the study: hormonal (e.g., oral, vaginal ring, transdermal patch, implant, or injection) consistently for at least 3 months prior to check-in (Day -1); double barrier method (e.g., condom with spermicide, diaphragm with spermicide) at screening; intrauterine device for at least 3 months prior to check-in (Day -1); a partner who has been vasectomized for at least 6 months prior to check-in (Day -1); abstinence beginning at least 6 months prior to screening.
8. A female subject of non-childbearing potential must be postmenopausal with amenorrhea for at least 1 year prior to check-in (Day -1) and follicle-stimulating hormone (FSH) levels consistent with postmenopausal status or have undergone one of the following sterilization procedures at least 6 months prior to check-in (Day -1): hysteroscopic sterilization; bilateral tubal ligation or bilateral salpingectomy; hysterectomy; bilateral oophorectomy.
9. Is willing to comply with the requirements of the study, including a willingness to use the study products during the study.

Exclusion Criteria:

1. Has a history or presence of clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, urologic, pulmonary, immunologic, psychiatric, or cardiovascular disease, or any other condition that, in the opinion of the investigator, would jeopardize the safety of the subject or impact the validity of the study results.
2. Has a clinically significant abnormal finding on the physical examination, medical history, vital signs, ECG, or clinical laboratory results, in the opinion of an investigator.
3. Has a positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV).
4. Has had an acute illness (e.g., upper respiratory infection, viral infection) requiring treatment within 14 days prior to check-in (Day -1).
5. Has a fever (\>100.5°F) at screening or check-in (Day -1).
6. Has a body mass index (BMI) \>40.0 kg/m2 or \<18.0 kg/m2 at screening.
7. Has a history of drug or alcohol abuse within 24 months of check-in (Day -1), as determined by an investigator.
8. Has or has a history of diabetes mellitus, asthma, or chronic obstructive pulmonary disease.
9. Has used prescription anti-diabetic medication and/or insulin therapy within 12 months prior to screening.
10. Has taken any medication for depression or asthma within 6 months prior to screening.
11. Has a systolic blood pressure \<90 or \>150 mmHg, diastolic blood pressure \<40 or \>95 mmHg, or heart rate \<40 or \>99 bpm at screening.
12. Has experienced an allergic reaction following previous e-cigarette use or with exposure to any primary components of the e-liquids (nicotine, flavor, benzoic acid, propylene glycol and glycerol).
13. Has an estimated creatinine clearance \<70 mL/minute (using the Cockcroft-Gault equation) at screening.
14. Has a positive urine screen for alcohol or drugs of abuse at screening or check-in (Day -1).
15. If female, the subject is pregnant, has a positive pregnancy test at screening, is lactating, or intends to become pregnant during the time period from screening through the end of study.
16. Has used medications known to interact with cytochrome P450 (CYP) 2A6 (including, but not limited to, amiodarone, amlodipine, amobarbital, buprenorphine, clofibrate, clotrimazole, desipramine, disulfiram, entacapone, fenofibrate, isoniazid, ketoconazole, letrozole, methimazole, methoxsalen, metyrapone, miconazole, modafinil, orphenadrine, pentobarbital, phenobarbital, pilocarpine, primidone, propoxyphene, quinidine, rifampicin, rifampin, secobarbital, selegiline, sulconazole, tioconazole, tranylcypromine) within 14 days or 5 half-lives of the drug, whichever is longer, prior to check-in (Day -1).
17. Has used nicotine-containing products other than manufactured cigarettes (e.g., ENDS products, roll-your-own cigarettes, bidis, snuff, nicotine inhaler, pipe, cigar, chewing tobacco, nicotine patch, nicotine spray, nicotine lozenge, or nicotine gum) within 30 days prior to check-in (Day -1).
18. Has any prior history of JUUL product use prior to screening.
19. Has used any prescription smoking cessation treatments, including, but not limited to, varenicline (Chantix®) or bupropion (Zyban®) within 3 months prior to check-in (Day -1).
20. Negative response (i.e., unwilling to use or unable to tolerate; e.g., experiences AEs (adverse events) during the product trial that will prevent the subjects from continuing to use the study products as judged by the investigator) to any of the JUUL products at screening.
21. Is a self-reported puffer (i.e., adult smokers who draw smoke from the cigarette into the mouth and throat but do not inhale).
22. Is planning to quit smoking during the study or postponing (within 30 days of screening) a quit attempt in order to participate in the study.
23. Has donated plasma within 7 days prior to check-in.
24. Has donated blood or blood products (with the exception of plasma as noted above), had significant blood loss, or received whole blood or a blood product transfusion within 56 days prior to check-in (Day -1).
25. Has participated in a previous clinical study for an investigational drug, device, biologic, or tobacco product within 30 days prior to check-in (Day -1).
26. Is or has a first-degree relative (i.e., parent, sibling, child) who is a current employee of the study site.
27. Is or has a first-degree relative (i.e., parent, sibling, child) who is a current employee, shareholder, or is member of the board of directors of JUUL Labs, Inc.
28. In the opinion of the Investigator, the subject should not participate in this study.
29. Has previously taken part in, has been excluded or withdrawn from, or has completed this study.

Primary outcomes:
measure: Nicotine uptake
timeFrame: 120 minutes
measure: Product liking as measured by the Product-Liking Questionnaire
timeFrame: 60 minutes
Secondary outcomes:
measure: Nicotine uptake
timeFrame: 120 minutes
measure: Nicotine uptake
timeFrame: 30 minutes
measure: Nicotine uptake
timeFrame: 60 minutes
measure: Nicotine uptake
timeFrame: 120 minutes
measure: The effects of nicotine exposure as measured by the Nicotine Withdrawal Questionnaire visual analog scale
timeFrame: 60 minutes
measure: The effects of nicotine exposure as measured by the Product Direct Effects Questionnaire
timeFrame: 60 minutes
measure: Subjective product assessments as measured by the Modified Product Evaluation Scale
timeFrame: 60 minutes
measure: Likelihood of future product use as measured by the Future Intent to Use the Product Questionnaire
timeFrame: 60 minutes
measure: E-cigarette product use
timeFrame: 5 minutes
measure: Physiologic impact of product use as measured by blood pressure
timeFrame: 60 minutes
measure: Physiologic impact of product use as measured by heart rate
timeFrame: 60 minutes
measure: Puff count during ad libitum (e-)cigarette use periods
timeFrame: 5 minutes
measure: Safety and tolerability of short-term product use assessed by monitoring the incidence of product-use emergent adverse events
timeFrame: 14 days
Other outcomes:
Locations:
city: Kansas City
country: United States
facility: Altasciences Clinical Kansas, Inc.
state: Kansas
city: Lexington
country: United States
facility: Central Kentucky Research Associates
state: Kentucky
Study officials:
References:
citation: Babb S, Malarcher A, Schauer G, Asman K, Jamal A. Quitting Smoking Among Adults - United States, 2000-2015. MMWR Morb Mortal Wkly Rep. 2017 Jan 6;65(52):1457-1464. doi: 10.15585/mmwr.mm6552a1.
citation: D'Ruiz CD, Graff DW, Robinson E. Reductions in biomarkers of exposure, impacts on smoking urge and assessment of product use and tolerability in adult smokers following partial or complete substitution of cigarettes with electronic cigarettes. BMC Public Health. 2016 Jul 11;16:543. doi: 10.1186/s12889-016-3236-1.
citation: Gottlieb S, Zeller M. A Nicotine-Focused Framework for Public Health. N Engl J Med. 2017 Sep 21;377(12):1111-1114. doi: 10.1056/NEJMp1707409. Epub 2017 Aug 16. No abstract available.
citation: Hatsukami DK, Zhang Y, O'Connor RJ, Severson HH. Subjective responses to oral tobacco products: scale validation. Nicotine Tob Res. 2013 Jul;15(7):1259-64. doi: 10.1093/ntr/nts265. Epub 2012 Dec 13.
citation: Jensen RP, Luo W, Pankow JF, Strongin RM, Peyton DH. Hidden formaldehyde in e-cigarette aerosols. N Engl J Med. 2015 Jan 22;372(4):392-4. doi: 10.1056/NEJMc1413069. No abstract available.
citation: McNeill A [et al.] E-cigarettes: an evidence update. A report commissioned by Public Health England [Report]. - 2015.
citation: Polosa R, Morjaria J, Caponnetto P, Caruso M, Strano S, Battaglia E, Russo C. Effect of smoking abstinence and reduction in asthmatic smokers switching to electronic cigarettes: evidence for harm reversal. Int J Environ Res Public Health. 2014 May 8;11(5):4965-77. doi: 10.3390/ijerph110504965.
citation: Tanner JA, Tyndale RF. Variation in CYP2A6 Activity and Personalized Medicine. J Pers Med. 2017 Dec 1;7(4):18. doi: 10.3390/jpm7040018.
citation: USDHH US Department of Health and Human Services The Health Consequences of Smoking- 50 Years of Progress: A Report of the Surgeon General [Book] / ed. Health National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and. - 2014.
citation: Wang TW, Asman K, Gentzke AS, Cullen KA, Holder-Hayes E, Reyes-Guzman C, Jamal A, Neff L, King BA. Tobacco Product Use Among Adults - United States, 2017. MMWR Morb Mortal Wkly Rep. 2018 Nov 9;67(44):1225-1232. doi: 10.15585/mmwr.mm6744a2.